171 related articles for article (PubMed ID: 25382057)
1. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.
Dawson H; Grundmann S; Koelzer VH; Galván JA; Kirsch R; Karamitopoulou E; Lugli A; Inderbitzin D; Zlobec I
Histopathology; 2015 Apr; 66(5):715-25. PubMed ID: 25382057
[TBL] [Abstract][Full Text] [Related]
2. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome.
Dawson H; Koelzer VH; Karamitopoulou E; Economou M; Hammer C; Muller DE; Lugli A; Zlobec I
Histopathology; 2014 Mar; 64(4):577-84. PubMed ID: 24111856
[TBL] [Abstract][Full Text] [Related]
3. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
4. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
5. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.
Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
Transl Res; 2015 Aug; 166(2):207-17. PubMed ID: 25797890
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):585-92. PubMed ID: 17239930
[TBL] [Abstract][Full Text] [Related]
7. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
11. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.
Douma S; Van Laar T; Zevenhoven J; Meuwissen R; Van Garderen E; Peeper DS
Nature; 2004 Aug; 430(7003):1034-9. PubMed ID: 15329723
[TBL] [Abstract][Full Text] [Related]
12. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
14. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.
Lugli A; Karamitopoulou E; Panayiotides I; Karakitsos P; Rallis G; Peros G; Iezzi G; Spagnoli G; Bihl M; Terracciano L; Zlobec I
Br J Cancer; 2009 Oct; 101(8):1382-92. PubMed ID: 19755986
[TBL] [Abstract][Full Text] [Related]
15. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
[TBL] [Abstract][Full Text] [Related]
16. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract][Full Text] [Related]
19. Activation of BDNF/TrkB pathway promotes prostate cancer progression via induction of epithelial-mesenchymal transition and anoikis resistance.
Li T; Yu Y; Song Y; Li X; Lan D; Zhang P; Xiao Y; Xing Y
FASEB J; 2020 Jul; 34(7):9087-9101. PubMed ID: 32390303
[TBL] [Abstract][Full Text] [Related]
20. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
